CA2324060A1 - Methods and compounds for modulating nuclear receptor activity - Google Patents

Methods and compounds for modulating nuclear receptor activity Download PDF

Info

Publication number
CA2324060A1
CA2324060A1 CA002324060A CA2324060A CA2324060A1 CA 2324060 A1 CA2324060 A1 CA 2324060A1 CA 002324060 A CA002324060 A CA 002324060A CA 2324060 A CA2324060 A CA 2324060A CA 2324060 A1 CA2324060 A1 CA 2324060A1
Authority
CA
Canada
Prior art keywords
atom
receptors
leu
receptor
nuclear receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002324060A
Other languages
English (en)
French (fr)
Inventor
Andrew Shiau
Peter J. Kushner
David A. Agard
Geoffrey L. Greene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Arch Development Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2324060A1 publication Critical patent/CA2324060A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
CA002324060A 1998-03-30 1999-03-30 Methods and compounds for modulating nuclear receptor activity Abandoned CA2324060A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7995698P 1998-03-30 1998-03-30
US60/079,956 1998-03-30
US11314698P 1998-12-16 1998-12-16
US11301498P 1998-12-16 1998-12-16
US60/113,146 1998-12-16
US60/113,014 1998-12-16
PCT/US1999/006937 WO1999050658A2 (en) 1998-03-30 1999-03-30 Methods and compounds for modulating nuclear receptor activity

Publications (1)

Publication Number Publication Date
CA2324060A1 true CA2324060A1 (en) 1999-10-07

Family

ID=27373576

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002324060A Abandoned CA2324060A1 (en) 1998-03-30 1999-03-30 Methods and compounds for modulating nuclear receptor activity

Country Status (6)

Country Link
EP (1) EP1144997A3 (ja)
JP (1) JP2002516983A (ja)
KR (1) KR20010042373A (ja)
AU (1) AU3457199A (ja)
CA (1) CA2324060A1 (ja)
WO (1) WO1999050658A2 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060014A2 (en) * 1998-03-30 1999-11-25 The Regents Of The University Of California Methods and compounds for modulating nuclear receptor coactivator binding
AU2818200A (en) * 1999-03-01 2000-09-21 Karo Bio Ab Homology models of the glucocorticoid receptor
EP1222459A4 (en) * 1999-10-14 2003-01-22 Bristol Myers Squibb Co CRYSTALLOGRAPHIC STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN
FR2801311B1 (fr) * 1999-11-22 2005-08-26 Centre Nat Rech Scient Polypeptides derives du recepteur nucleaire de la vitamine d, et leurs utilisations notamment dans le cadre du criblage d'analogues de la vitamine d
CA2415103A1 (en) * 2000-06-30 2002-01-10 The Regents Of The University Of California Methods and compounds for modulating nuclear receptor coactivator binding
DE10036461A1 (de) * 2000-07-25 2002-02-07 Bayer Ag Ligandenbindedomäne des Ultraspiracle (USP)-Proteins
JP4593754B2 (ja) * 2000-10-13 2010-12-08 一般財団法人 化学物質評価研究機構 化学物質の５０％阻害濃度決定方法
JP2002296282A (ja) * 2001-04-02 2002-10-09 Enbiotec Laboratories:Kk 外因性内分泌攪乱物質の検出方法
WO2003005025A1 (en) * 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
GB0209507D0 (en) * 2002-04-25 2002-06-05 Karobio Ab Nuclear receptor structure
US7302347B2 (en) * 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
JPWO2005022436A1 (ja) * 2003-08-29 2006-10-26 独立行政法人産業技術総合研究所 蛋白質機能発現機構表示のための蛋白質構造三次元表示システム
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
WO2005040212A2 (en) * 2003-10-24 2005-05-06 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Orthogonal gene switches
CN102905685A (zh) * 2010-03-31 2013-01-30 株式会社爱茉莉太平洋 含有香豆雌酚或包含香豆雌酚的豆提取物的、用于皮肤护理的化妆品组合物
ES2627692T3 (es) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Moduladores de receptores de estrógenos y usos de los mismos
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
ES2097925T3 (es) * 1991-09-18 1997-04-16 Affymax Tech Nv Metodo para sintetizar diversas colecciones de oligomeros.
EP0705279B1 (en) * 1993-05-27 2003-02-19 Selectide Corporation Topologically segregated, encoded solid phase libraries
IL106106A0 (en) * 1993-06-22 1993-10-20 Interpharm Lab Ltd Library of polymeric molecules and its preparation
CA2240024A1 (en) * 1995-12-13 1997-06-19 The Regents Of The University Of California Nuclear receptor ligands and ligand binding domains

Also Published As

Publication number Publication date
WO1999050658A3 (en) 2001-08-16
JP2002516983A (ja) 2002-06-11
EP1144997A3 (en) 2002-08-28
WO1999050658A2 (en) 1999-10-07
AU3457199A (en) 1999-10-18
KR20010042373A (ko) 2001-05-25
EP1144997A2 (en) 2001-10-17

Similar Documents

Publication Publication Date Title
CA2324060A1 (en) Methods and compounds for modulating nuclear receptor activity
AU768513B2 (en) Methods and compounds for modulating nuclear receptor coactivator binding
Wong et al. Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound to the anti-protozoan drug emetine
Dauden et al. Architecture of the yeast Elongator complex
AU775928B2 (en) Crystallographic structure of the androgen receptor ligand binding domain
Dauter et al. Practical experience with the use of halides for phasing macromolecular structures: a powerful tool for structural genomics
WO2017117118A1 (en) Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
Lu et al. Conformational landscape of the p28-bound human proteasome regulatory particle
Kosteria et al. The use of proteomics in assisted reproduction
EP1034184A2 (en) Nuclear receptor ligands and ligand binding domains
Sun et al. Research advances in hydrogen–deuterium exchange mass spectrometry for protein epitope mapping
AU2014361662A1 (en) Systems and methods of selecting compounds with reduced risk of cardiotoxicity
US20090088554A1 (en) Hdm2-inhibitor complexes and uses thereof
Wang et al. Pan-cancer analysis of voltage-dependent anion channel (VDAC1) as a cancer therapeutic target or diagnostic biomarker
WO2002002488A9 (en) Methods and compounds for modulating nuclear receptor coactivator binding
WO2015032776A1 (en) Method for improving antibody stability
Trauger et al. Investigating viral proteins and intact viruses with mass spectrometry
AU2003262215A1 (en) Methods and compounds for modulating nuclear receptor activity
Suchanova et al. Folding and assembly of large macromolecular complexes monitored by hydrogen-deuterium exchange and mass spectrometry
Anderson et al. Intact protein analysis at 21 Tesla and X-ray crystallography define structural differences in single amino acid variants of human mitochondrial branched-chain amino acid aminotransferase 2 (BCAT2)
WO2002048898A1 (en) Method for screening for inhibitors of alzheimer's disease
EP1181393A2 (en) CRYSTAL STRUCTURE OF RIBOSOMAL PROTEIN L11/GTPASE ACTIVATING REGION rRNA AND USES THEREOF
Tessier et al. Structural and functional validation of a highly specific Smurf2 inhibitor
Wiklund Metabolomics and prostate cancer
CA2564584A1 (en) Hdm2-inhibitor complexes and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead